Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 296, Issue 2, 2009, Pages

  De Boer, Jan Freark ^a   Bahr, Matthias J ^b   Böker, Klaus H W ^b   Manns, Michael P ^b   Tietge, Uwe J F ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adipokines; Erase; Human; Metabolism; Nicotinamide phosphoribo; Pre b cell colony enhancing factor

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ADULT; ARTICLE; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; GENE EXPRESSION; GLUCOSE OXIDATION; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER LEVEL; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADIPOKINES; BLOOD GLUCOSE; BODY COMPOSITION; CASE-CONTROL STUDIES; CYTOKINES; DOWN-REGULATION; ENERGY METABOLISM; FEMALE; GLUCOSE; HUMANS; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; KETONE BODIES; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX;

EID: 59449089235     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00029.2008     Document Type: Article

References (35)

1. Arner P. Visfatin-a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 91: 28-30, 2006.
2. Axelsson J, Witasp A, Carrero JJ, Qureshi AR, Suliman ME, Heim- burger O, Barany P, Lindholm B, Alvestrand A, Schalling M, Nord- fors L, Stenvinkel P. Circulating levels of visfatin/pre-B-cell colony- enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 49: 237-244, 2007.
3. Bahr MJ, Ockenga J, Böker KHW, Manns MP, Tietge UJF. Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance. Am J Physiol Endocrinol Metab 291: E199-E206, 2006.
4. Basu A, Shah P, Nielsen M, Basu R, Rizza RA. Effects of type 2 diabetes on the regulation of hepatic glucose metabolism. J Investig Med 52: 366-374, 2004.
5. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M. Plasma visfatin concentrations and fat depot- specific mRNA expression in humans. Diabetes 54: 2911-2916, 2005.
6. Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J, McDonagh T, Lemieux M, McBurney M, Szilvasi A, Easlon EJ, Lin SJ, Guarente L. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 4: e31, 2006.
7. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91: 295-299, 2006.
8. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsu- zawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430, 2005.
9. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91: 1578 -1581, 2006.
10. Manco M, Fernandez-Real JM, Equitani F, Vendrell J, Mora MEV, Nanni G, Tondolo V, Calvani M, Ricart W, Castagneto M, Mingrone G. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 92: 483-490, 2007.
11. McCullough AJ, Raguso C. Effect of cirrhosis on energy expenditure. Am J Clin Nutr 69: 1066-1068, 1999.
12. Moscatiello S, Manini R, Marchesini G. Diabetes and liver disease: an ominous association. Nutr Metab Cardiovasc Dis 17: 63-70, 2007.
13. Moynihan KA, Grimm AA, Plueger MM, Bernal-Mizrachi E, Ford E, Cras-Meneur C, Permutt MA, Imai S. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab 2: 105-117, 2005.
14. Muller MJ, Boker KHW, Selberg O. Metabolism of energy-yielding substrates in patients with liver cirrhosis. Clin Investig 72: 568 -579, 1994.
15. Muller MJ, Bottcher J, Selberg O, Weselmann S, Böker KHW, Schwarze M, von zur Mühlen A, and Manns MP. Hypermetabolism in clinically stable patients with liver cirrhosis. Am J Clin Nutr 69: 11941201, 1999.
16. Perseghin G, Caumo A, Mazzaferro V, Pulvirenti A, Sereni LP, Romito R, Lattuada G, Coppa J, Costantino F, Regalia E, Luzi L. Assessment of insulin sensitivity based on a fasting blood sample in men with liver cirrhosis before and after liver transplantation. Transplantation 76: 697-702, 2003.
17. Petrides AS, DeFronzo RA. Glucose and insulin metabolism in cirrhosis. J Hepatol 8: 107-114, 1989.
18. Pilz S, Mangge H, Obermayer-Pietsch B, Marz W. Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions. J Endocrinol Invest 30: 138-144, 2007.
19. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 23: 164-170, 2007.
20. Roden M, Bernroider E. Hepatic glucose metabolism in humans-its role in health and disease. Best Pract Res Clin Endocrinol Metab 17: 365-383, 2003.
21. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC- 1alpha and SIRT1. Nature 434: 113-118, 2005.
22. Sakka SG. Assessing liver function. Curr Opin Crit Care 13: 207-214, 2007.
23. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony- enhancing factor. Mol Cell Biol 14: 1431-1437, 1994.
24. Shmueli E, Record CO, Alberti KGMM. Liver disease, carbohydrate metabolism and diabetes. Clin Endocrinol Metab 6: 719 -744, 1992.
25. Stephens JM, Vidal-Puig AJ. An update on visfatin/pre-B cell colony- enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 17: 128 -131, 2006.
26. Sturmvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333-1346, 2005.
27. Sun G, Bishop J, Khalili S, Vasdev S, Gill V, Pace D, Fitzpatrick D, Randell E, Xie YG, Zhang H. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 85: 399-404, 2007.
28. Taki Y, Gubernatis G, Yamaoka Y, Oellerich M, Yamamoto Y, Ringe B, Okamoto R, Bunzendahl H, Beneking M, Burdelski M. Significance of arterial ketone body ratio measurement in human liver transplantation. Transplantation 49: 535-539, 1990.
29. Tietge UJF, Bahr MJ, Manns MP, Boker KHW. Altered alanine plasma levels despite normalized hepatic alanine extraction in the long-term course after liver transplantation. Transplantation 75: 804-810, 2003.
30. Tietge UJF, Bahr MJ, Manns MP, Boker KHW. Decreased splanchnic oxygen uptake and increased systemic oxygen uptake in cirrhosis are normalized after liver transplantation. Liver Transpl 7: 1015-1022, 2001.
31. Tietge UJF, Boker KHW, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 287: E82-E89, 2004.
32. Tietge UJF, Selberg O, Kreter A, Bahr MJ, Pirlich M, Burchert W, Muller MJ, Manns MP, Boker KHW. Alterations in glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation. Liver Transpl 10: 1030 -1040, 2004.
33. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ, Starks T, Kern LM, Spencer HJ, McGehee RE, Fried SK, Kern PA. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 92: 666-672, 2007.
34. Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol 13: 661-662, 2006.
35. Yamamoto S, Nitta N, Ozaki N, Morimoto T, Kamiyama Y, Yamaoka Y, Okanoue T, Ozawa K. Deleterious effects of splanchnic congestion on hepatic energy metabolism following repeated portal triad cross-clamping in dogs. Circ Shock 26: 193-201, 1988.